Bristol-Myers Squibbs (NYSE: BMY)revenue grew from $19.4 billion in 2016 to $26.1 billion in 2019, and it is estimated to top $42 billion in 2020. This growth will primarily be driven by its oncology drugs portfolio, which will likely get over a 2x boost in 2020, due to the impact of the Celgene acquisition. Bristol-Myers Squibbs oncology drugs segment is expected to be the single-biggest revenue driver with $27.7 billion in revenues (66% of total revenues), which is over 3x the size of Cardiovascular, Bristol-Myers Squibbs second largest business segment, in 2020. Oncology drugs, which includes blockbuster drugs Revlimid and Opdivo, among other drugs, will be the fastest-growing segment adding $19.2 billion over 2017-20 (90% of the $21.3 billion in incremental revenues). Cardiovascular, which includes Eliquis, will add about $4.1 billion over 2017-20 (19% of the $11.5 billion in incremental revenue), and immunology drugs will add $1.0 billion (5% of incremental revenues). This will likely be offset by an expected decline of $3.0 billion (-14% of incremental revenue) in all other drugs segment. In this analysis, BMY Revenues: How Does Bristol-Myers Squibb Make Money?, we focus on Bristol-Myers Squibbs business model, its revenue segments, their historical performance, forecast for 2021, and peer comparison, parts of which are highlighted below.

Bristol-Myers Squibb (BMS) 2020 Revenues To Surge After Celgene Acquisition

BMS Has A Large Oncology Drugs Portfolio, Courtesy of Celgene

BMS Is Gaining Market Share In Cardiovascular Drugs Market

Immunology Portfolio Could See Biosimilar Competition In 2021

All Other Drugs Sales Will Continue To Decline

Impact of Coronavirus

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams

See the article here:
What Will Drive Bristol-Myers Squibb's $42 Billion Revenue In 2020? - Trefis